infection caused News
-
Are Infections Caused by Aspergillus Fungi Developing Drug Resistance?
A study recently published in the journal, Clinical Infectious Diseases, discovered azole-resistance markers in 75% of a small group of aspergillosis patients who had not previously been treated with an azole. The research was conducted by the University of Manchester working with colleagues in the United States. Aspergillosis is the disease cause by Aspergillus. According to the Centers ...
-
MerLion Pharmaceuticals Announces Successful FDA Type C Meeting for the Systemic Application of the Antibiotic Finafloxacin Against Infections caused by Burkholderia pseudomallei (Melioidosis)
MerLion Pharmaceuticals GmbH (MerLion), a pharmaceutical company focused on the development of novel antibiotics, reported the receipt of the final meeting minutes from the U.S. Food and Drug Administration (FDA) following a successful Type C meeting with the Agency on the development of the antibiotic finafloxacin for the treatment of melioidosis, in a naturally occurring as well as a biodefense ...
-
Tainted Medical Wipes Lawsuit Settled by Parents of Dead Toddler
The parents of Harrison Kothari, a two-year old who died from a bacterial infection caused by contaminated medical wipes, have settled a lawsuit with the Wisconsin companies that made and distributed them. The wipes, manufactured by H&P Industries, Inc. and sold by the Triad Group, were recalled in February 2011 after they were found to be contaminated by the rare bacterium Bacillus cereus. ...
-
CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent superbug infections that cause life-threatening pneumonia and other deadly infections
CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia. Vaxdyn is the first Spanish biotech to be funded by CARB-X, a non-profit partnership investing $500 million in the development of innovative vaccines, ...
-
The Provincial Government of Tainan has bought 80 of our state-of-the-art UV Air sterilization products
Giving back to our community has always been our long-standing commitment. This is why I’m thrilled to announce the launch of our state-of-the-art, TOP MULTI LIZER, a UV Air Sterilization product into the Taiwanese market. “I am extremely humbled at the support extended by the Health Ministry, in particular Tainan city, through the purchase of 80 of our revolutionary products to ...
-
NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine Against Candida
GRAND FORKS, N.D. – October 3, 2013 – NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has closed a $14M Series B financing. Participating investors included new investor RusnanoMedInvest (RMI) and current investor Domain Associates. The proceeds from this financing will be used to conduct an ongoing Phase 2 ...
-
Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022. The on demand presentation will be available, beginning Monday, January 10, 2022 at 7:00 a.m. E.T. and may ...
-
Dynavax to Present at the Cowen 42nd Annual Health Care Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, at 2:50 p.m. E.T. The presentation will be webcast ...
-
Dynavax to Present at the H.C. Wainwright Global Investment Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022. The on demand presentation will be available, beginning Tuesday, May 24, 2022 at 7:00 a.m. E.T. ...
-
New respiratory multitest
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory Syncytial Virus (RSV) ...
-
Genano signs agreement to expand operations in China
Last week, during China International Import Expo in Shanghai China, Genano Ltd signed a new distributor agreement with its long term China Partner Jiangsu Holly Group. Since 2015, Genano and Jiangsu Holly Group have executed several successful hospital projects in China, in the area of infection control and prevention of nosocomial infections caused by airborne pathogens. This new contract is ...
-
Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat during the William Blair 42nd Annual Growth Stock Conference in Chicago, Illinois on Monday June 6, 2022 at 4:40 ...
-
Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Monday, February 28, 2022 at 4:30 p.m. ...
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 16,000 shares of Dynavax common stock as inducements to 2 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on March 1, 2022, at an exercise price of $12.21 per share, which is equal to the ...
-
Exposure to Pigeons may lead to Fungal Infections in Humans
Cryptococcosis is the disease caused by the fungus known as Cryptococcus. Cryptococcus is a fungus that is found in the soil, usually in association with bird droppings. The major species of Cryptococcus that causes illness in human is Cryptococcus neoformans, which is found worldwide. Another less common species, that can also cause disease in humans, is Cryptococcus gattii. Since 1999, ...
-
Cyclospora & Infection Risks Discussed in New Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses Cyclospora cayetanensis, a parasite composed of one cell that causes an intestinal infection called cyclosporiasis. “Earlier this year, an outbreak associated with Cyclospora and contaminated cilantro infected close to 500 people in 30 ...
-
Illinois Healthcare Facilities on the Lookout for VRE Infections
According to the Centers for Disease Control and Prevention (CDC), one out of every twenty hospital patients acquires an infection while being treated for another illness. Reducing healthcare-associated infections (HAIs) has become a central focus of the CDC in recent years and many healthcare facilities across Illinois have been on the frontline of these efforts. Healthcare-associated ...
-
WHO calls for new innovations to tackle antimicrobial resistance crisis
Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has been proven in Canadian hospitals to kill pathogens helping to generate 84% reduction of postoperative infection rates and significant cost savings. The World ...
-
Mid-Atlantic Infection Control Professionals Help Healthcare Facilities Battle VRE
As healthcare-associated infections (HAIs) receive increased attention by the U.S. Centers for Disease Control and Prevention (CDC) and the national media, healthcare facilities are under increased pressure to prevent their spread. Many of the national media reports have focused on Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff), but many other pathogens ...
-
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces completion of the Phase I clinical trial for ALS-4 (a first in-class anti-virulence based small molecule drug targeting infections caused by ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you